Podcasts about Genomics

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today we are featuring two articles that relate to moving genetics into mainstream healthcare. In our first segment, we discuss polygenic risk scores and the transition from research to clinical use. Our second segment focuses on hypermobility Ehlers Danlos Syndrome and the triaging of clinical referrals.    Segment 1: Readiness and leadership for the implementation of polygenic risk scores: Genetic healthcare providers' perspectives in the hereditary cancer context   Dr Rebecca Purvis is a post-doctoral researcher, genetic counsellor, and university lecturer and coordinator at The Peter MacCallum Cancer Centre and The University of Melbourne, Melbourne, Australia. Dr Purvis focuses on health services delivery, using implementation science to design and evaluate interventions in clinical genomics, risk assessment, and cancer prevention.   In this segment we discuss: - Why leadership and organizational readiness are critical to successful clinical implementation of polygenic risk scores (PRS). - How genetic counselors' communication skills position them as key leaders as PRS moves from research into practice. - Readiness factors healthcare systems should assess, including culture, resources, and implementation infrastructure. - Equity, standardization, and implementation science as essential tools for responsible and sustainable PRS adoption. Segment 2: A qualitative investigation of Ehlers-Danlos syndrome genetics triage   Kaycee Carbone is  a genetic counselor at Boston Children's Hospital in the Division of Genetics and Genomics as well as the Vascular Anomalies Center. Her clinical interests include connective tissue disorders, overgrowth conditions, and somatic and germline vascular anomaly conditions. She completed my M.S. in Genetic Counseling at the MGH Institute of Health Professions in 2023. The work she discusses here, "A qualitative investigation of Ehlers-Danlos syndrome genetics triage," was completed as part of a requirement for this graduate program.    In this segment we discuss: - Why genetics clinics vary widely in how they triage referrals for hypermobile Ehlers-Danlos syndrome (hEDS). - How rising awareness of hEDS has increased referral volume without clear guidelines for diagnosis and care. - The ethical and emotional challenges genetic counselors face when declining hEDS referrals. - The need for national guidelines and clearer care pathways to improve access and coordination for EDS patients. Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield.

In this explainer episode, we've asked Dr Katie Snape, principal clinician at Genomics England, cancer geneticist, and specialist in inherited cancer, to explain how genomics can help us understand cancer. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Flo: How can genomics help us understand cancer?   I'm Florence Cornish, and today I'm joined with Katie Snape, who is Principal Clinician here at Genomics England, lead Consultant for Cancer Genetics at the Southwest Thames Centre for Genomics, and Chair of UK Cancer Genetics Group. So Katie, it's probably safe to say that everyone listening will have heard the word cancer before. Lots of people may have even been directly affected by it or know someone who has it or who has had it, and I think the term can feel quite scary sometimes and intimidating to understand. So, it might be good if you could explain what we actually mean when we say the word cancer.   Katie: Thanks, Florence. So, our bodies are made up of millions of building blocks called cells. Each of these cells contains an instruction manual, and our bodies read this to build a human and keep our bodies working and growing over our lifetimes. So, this human instruction manual is our genetic information, and it's called the human genome. Throughout our lifetime, our cells will continue to divide and grow to make more cells when we need them. And this means that our genetic information has to contain the right instructions, which tell the cells to divide when we need new cells, like making new skin cells, for example as our old skin cells die, but they also need to stop dividing when we have enough new cells and we don't need anymore. And this process of growing but stopping when we don't need anymore cells, keeps our bodies healthy and functioning as they should do. However, if the instructions for making new cells goes wrong and we don't stop making new cells when we're supposed to, then these cells can grow out of control, and they can start spreading and damaging other parts of our body. And this is basically what cancer is. It's an uncontrolled growth of cells which don't stop when they're supposed to, and they grow and spread and damage other tissues in our body. Florence: So, you mentioned there that cancer can arise when the instructions in our cells go wrong. Could you talk a little bit more about this? How does it lead to cancer? Katie: Yeah. So the instructions that control how our cells should grow and then stop growing are usually called cancer genes. So our body reads these instructions a bit like we might read an instruction manual to perform a task. So if we imagine that one of these important cancer genes that has a spelling mistake, which means the body can't read it properly, then those cells won't follow the right instructions to grow and then stop growing like they should. So if our cells lose the ability to read these important instructions due to this type of spelling mistake, then that's when a cancer can develop. As these spelling mistakes happen in cancer genes, we call them genetic alterations or genetic variants. Florence: And so, when you're in the clinic seeing somebody who has cancer, what kinds of genomic tests can they have to help us find out a little bit more about it? Katie: So the genetic alterations that can cause cancer can happen in different cells. So that's why cancer can affect many different parts of the body. If a genetic alteration happens in a breast cell, then a breast cancer might develop. If the alteration happens in a skin cell, then a skin cancer could develop. We can take a sample from the cancer. This is often known as a biopsy, and then we can use this sample to extract the genetic information to read the instructions in the cancer cells, and when we do this, we are looking for spelling mistakes in the important cancer genes, which might of course, those cells to grow out of control. We can also look for patterns of alterations in the cells, which might tell us the processes that led to those genetic alterations occurring. For example, we can look at patterns of damage in the genetic information caused by cigarette smoke, or sunlight, or problems because the cell has lost its ability to mend and repair its genetic information. And we can also count the number of different alterations in the cancer cell, which might tell us how different that cancer cell is from our normal cells, and that can be important because we might be able to use medications to get our immune system to attack the cancer cells. So where we see genetic alterations in a cancer cell, we call them acquired or somatic alterations because we weren't born with them, but they've happened in a cell in our body at a later stage, and they've caused those cells to become uncontrollable and to keep growing. Sometimes people can be born with a genetic alteration in a cancer gene that significantly increases the chance of them developing cancer in their lifetime. This type of genetic alteration can be inherited, and so these changes can be shared by relatives. If we see more cancer in a family than we would expect by chance, or unusually young cancers or patterns of cancer, or there are other signs that a cancer patient might have an inherited cancer gene causing their cancer, then we can offer a test to check for this as well. Florence: And so, when we do these tests, what are we looking for specifically? What is it that we're trying to find out about a person's cancer that could help us to treat it as effectively as possible? Katie: So all of these genetic tests are helping us understand why a cancer has developed and what are the underlying changes that cause the cells to grow out of control. If we understand why the cancer developed, we can choose medications to try and treat the cancer and these specifically target the underlying problems in the cell, and hopefully attack the cancer cells, but not the normal cells in the body. We call this precision or personalised medicine. Many newer cancer drugs specifically target the changes that have occurred in the cancer cells as part of this process for becoming cancer, and they kill those that carry specific genetic changes which have caused those cells to grow uncontrollably. Florence: I wanted to ask you now about inherited cancer risk. So by this we mean if a parent has a change in one of their genes that increases their risk of developing cancer, there's a possibility that they can then pass this gene along to their children. Is there anything we can do to manage these inherited risks? Katie: If a person has an inherited change, increasing cancer risk, we can offer them programs to help reduce that risk. There are different things that we might offer them. So, for example, for some conditions we have preventative medication. There is a condition called Lynch syndrome, which is due to a change in some cancer genes, and people who have Lynch syndrome have a high chance of developing bowel and womb cancers, amongst others. For people with Lynch syndrome, they can take a daily low dose aspirin, and this reduces their chance of developing a bowel cancer by about a half. Or in other cases, we can offer extra screening and that will allow us to catch any cancers that do occur at an earlier stage when they're more likely to be more effectively treated. So for example, if someone has a high risk of breast cancer, we could offer them extra and more frequent screening of their breast. Another option is we could offer risk reducing surgery. So, for example, if someone had a higher chance of developing ovarian cancer after the age of 50, we could offer removal of the tubes and ovaries as their chance of cancer starts to increase, and that would significantly reduce their risk of developing cancer in the future.  Florence: And, working in this space, you and I know that research groups are working all the time to try and better understand cancer and how we might be able to treat it more effectively. Could you tell me about how genomics in particular is helping to advance the detection and treatment of cancer?  Katie: Genomics is helping develop both our understanding of how and why cancer develops, and as well as that, it's also helping us find new cancer treatments all the time.   There are already many drugs that are available to cancer patients that specifically target the genetic changes found in their cancer. In addition to that, there are many clinical trials now for cancer patients, which use the information from genomic sequencing to help guide new research into better treatments based on the genetic alterations in the cancer cell.  We are increasingly using genetic testing to identify more at-risk people with inherited changes in the population as well, so that we can make sure if they have a higher chance of developing cancer in their lifetime, that they get the best prevention and screening programs available. our understanding of genomics is really impacting both our understanding of what causes cancer, how we treat it, and how we can prevent it as well.  Florence: So, I think we'll finish there. Katie, it's been so great to talk to you and to learn more about why genomics is proving to be so important in helping us to understand cancer.   If listeners want to hear more, explain episodes like this, you can find them on our website@www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening. 

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Are you trying to break into medical sales but stuck deciding between Pharmaceutical and Medical Device? Or maybe you're curious about the high-growth world of Diagnostics and Genomics?Today, we discuss the differences in pay, lifestyle, and entry-level requirements for each path. Whether you want the adrenaline of the Operating Room or the stability of a $130k+ base salary in Pharma, this episode covers the 12 key distinctions you need to know before applying. IN THIS EPISODE YOU WILL LEARN:The Personality Test: Why "Engineers" love Device and "Scientists" love Pharma.The Paycheck: Real breakdown of base salaries vs. uncapped commissions.The Hidden Third Option: Why Oncology Diagnostics/Genomics might be the "Goldilocks" career path.Work-Life Balance: The reality of on-call surgical hours vs. the 9-to-5 pharma life.Success Stories: How a nurse (Sydney) and an immigrant (Kanika) broke in with $150k-$200k packages.READY TO BREAK IN? If you are struggling to get offers or don't know where to start, we help people from all backgrounds (nurses, coaches, teachers) launch their medical sales careers.Apply to Medical Sales U at medicalsalesu.com/TIMESTAMPS:00:00 - Intro: The common dilemma (O.R. vs. Samples).01:06 - The 3 Paths: Pharma, Device, and Diagnostics.02:15 - Science vs. Engineering: Which fits your brain?04:35 - Salary Reveal: Entry-level Pharma Pay ($95k-$135k base).06:10 - The "Associate" Role: Why Device base pay starts lower.07:40 - The Top 1%: Earning potential ($300k - $750k).09:15 - Diagnostics Pay: The sweet spot?10:30 - The Sales Process: Who are you actually selling to?13:50 - Lifestyle Check: Early mornings vs. Family flexibility.17:15 - Career Advancement: From Rep to Regional Director.22:15 - Student Success: From $68k to $200k total comp.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US:Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #PharmaceuticalSales #MedDevice #SalesCareer #DaveSterritt #CareerAdvice #HighPayingJobs #SalesTips

The future of cancer care is shifting toward earlier detection, continuous monitoring, and truly personalized treatment powered by high-quality genomic insights. In this episode, Ajay Gannerkote, President of Integrated DNA Technologies, explains how rapid advances in genomics are transforming cancer diagnosis, precision medicine, and personalized care. He describes how IDT evaluates emerging technologies by combining custom manufacturing, high-quality reagents, and deep scientific partnerships to deliver clinically meaningful insights. Ajay highlights how NGS, MRD, and multi-cancer detection are expected to accelerate over the next 3–5 years, enabling far earlier diagnosis and more precise monitoring. He also underscores the power of collaboration, shares a rare pediatric success story, and reflects on leadership principles centered on trust, innovation, and an “obligation to dissent.” Tune in and learn how the next wave of genomic innovation is bringing precision medicine within reach for patients everywhere! Resources Connect with and follow Ajay Gannerkote on LinkedIn. Follow Integrated DNA Technologies on LinkedIn and visit their website!

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week on the Unsupervised Learning Podcast, Razib talks to returning guest Alex Young of UCLA and Herasight. Trained originally as a mathematician, Young studied statistics and computational biology at the University of Cambridge before doing a doctorate in genomic medicine and statistics at the Wellcome Trust Centre for Human Genetics, University of Oxford, under Peter Donnelly. He also worked at deCODE Genetics in Reykjavik and at Oxford with Augustine Kong, developing methods in quantitative and population genetics. Razib and Young talk extensively about what we know about heritability and genomics in 2025, four years after their first conversation. In particular, they discuss what larger sample sizes, high-density genotype-arrays and whole-genome sequencing have told us about heritability and the ability to predict traits in individuals from their sequence. They discuss quantitative and behavioral traits like height, intelligence and risk of autism, and the differences between classical statistical genetical methods utilizing twins and modern molecular genomic techniques that attempt to fix specific physical markers as causal factors in characteristics of interest. In addition to his academic work, Young has also been consulting for the polygenic embryo-screening company Herasight, working on cutting-edge methods for genomic prediction in the context of in vitro fertilization. They dig deep into the new method Young and colleagues worked on that helps democratize embryo selection using genomics, ImputePGTA.

California scientists are uncovering the genetic drivers behind better black-eyed pea performance.

Anthony Ginsberg, CEO of GinsGlobal Index Fund, recently spoke with Steve Darling from Proactive about the latest developments shaping the Tech Megatrend ETF and the powerful forces driving performance across some of the world's fastest-moving technology sectors. Ginsberg outlined how the fund continues to evolve in step with emerging innovation while benefiting from broad macroeconomic tailwinds. Ginsberg explained that the ETF has recently expanded its thematic coverage to include both defense technology and quantum computing, further diversifying its exposure to high-growth innovation areas. These additions complement the fund's established themes, which include cloud computing, digital entertainment, blockchain, and social media. He highlighted blockchain as a standout performer, noting that the segment has risen more than 50%. “Blockchain… has been up over 50%,” Ginsberg said, adding that strong contributions from digital entertainment and cloud computing have also supported overall performance. He also pointed to growing strength in genomics and gene editing, emphasizing how artificial intelligence is transforming research and development activity across biotechnology. Ginsberg explained that AI is dramatically accelerating drug discovery and development timelines, allowing technologies such as CRISPR gene editing to advance far more rapidly than traditional pharmaceutical approaches. This convergence of AI and biotech, he noted, is creating a powerful new growth engine within the broader tech ecosystem. Beyond sector-specific trends, Ginsberg discussed several macro factors providing tailwinds for the technology market. These include easing inflation, the expectation of interest rate cuts, a weaker U.S. dollar, and a pickup in mergers and acquisitions as regulatory conditions shift. He cited Netflix's acquisition of Warner Brothers as an example of the ongoing global convergence across digital media and content platforms, a trend he believes is still in its early stages. He also noted that valuations in small- and mid-cap technology companies remain attractive relative to long-term growth potential. Looking ahead to 2026, Ginsberg sees continued expansion of artificial intelligence across multiple verticals, including cloud computing, cybersecurity, hyperscalers, and digital entertainment. He added that surging demand for data-center infrastructure is providing strong underlying support for this growth, reinforcing the long-term investment case for the technology megatrend. #TechMegatrendETF, #AnthonyGinsberg, #FourthIndustrialRevolution, #AI, #Cybersecurity, #CloudComputing, #SocialMedia, #FutureCars, #Robotics, #InterestRateCuts, #Diversification, #GlobalHoldings, #Nasdaq,

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

About Ajay Gannerkote:Ajay Gannerkote is a global healthcare leader with deep experience spanning life sciences, medical devices, and healthcare services. Now serving as president of Integrated DNA Technologies (IDT), a Danaher company, he oversees the organization's growth and strategic direction from Redwood City, California. Before IDT, he led Siemens Healthineers' global ultrasound business as president and head, steering a complex, vertically integrated operation across more than 30 countries. Under his leadership, the business moved from negative growth and margins to strong, sustainable performance, becoming an industry leader in AI-driven clinical technology. Prior to that, he served as Director at KKR Capstone, where he co-led healthcare operations, drove large-scale transformations for portfolio companies, and created significant enterprise value across services and medical device sectors. Ajay spent more than a decade at McKinsey & Company as a partner in the Global Medical Products practice, advising Fortune 500 companies on product development, commercialization, operations, growth strategy, and large-scale turnarounds. Earlier in his career, he held leadership roles at Federal-Mogul, Cambridge Technology Partners, and Infosys, building a foundation in operations, technology, and global business integration. He holds an MBA in Corporate Strategy and Marketing from the University of Michigan's Ross School of Business and a bachelor's degree in Electronics and Telecommunications Engineering from the University of Mysore.Things You'll Learn:Genomic technologies, such as NGS and MRD, are enabling earlier cancer detection, sometimes years ahead of traditional diagnostic methods. This early visibility allows clinicians to intervene sooner and build more personalized treatment strategies.Precision medicine is rapidly maturing as high-quality genomic data becomes central to diagnosis, monitoring, and therapy planning. The next era of oncology will rely heavily on personalized, data-driven decisions.Collaboration across industry, researchers, and regulatory bodies is essential for breakthrough medical innovations. A recent case of a rare disease demonstrates how a coordinated effort can compress the journey from diagnosis to therapy into just a few months.Custom manufacturing and high-quality reagents are critical enablers of clinically reliable genomic insights. Tailored solutions allow researchers and clinicians to analyze tumor-specific markers with greater accuracy and confidence.Strong leadership in genomics requires trust, transparency, and a willingness to challenge assumptions. Ajay's “obligation to dissent” principle encourages continuous innovation and pushes teams to think beyond the status quo.Resources:Connect with and follow Ajay Gannerkote on LinkedIn.Follow Integrated DNA Technologies on LinkedIn and visit their website.

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sophie sits down with Erika Gray, co-founder of Toolbox Genomics, to break down how your genes affect detoxification, your ability to clear hormones, toxins, histamine, caffeine, and more.They talk about what happens when detox pathways run too fast or too slow, why environment matters just as much as genetics, and how understanding your unique blueprint can make detox and supplementation actually work better.Sophie also shares details about their new collaboration, where you can run your Detoxification Panel through Toolbox Genomics and get a personalized detox plan created just for you.Connect with Toolbox Genomics:toolboxgenomics.comWork with Sophie:shetalkshealth.comDisclaimer: This information is being provided to you for educational and informational purposes only. It is being provided to educate you about how to take care of your body and as a self-help tool for your own use so that you can reach your own health goals. It is not intended to treat or cure any specific illness and is not to replace the guidance provided by your own medical practitioner. If you are under the care of a healthcare professional or currently use prescription medications, you should discuss any dietary changes or potential dietary supplement use with your doctor, and should not discontinue any prescription medications without first consulting your doctor. This information is to be used at your own risk based on your own judgment. If you suspect you have a medical problem, we urge you to take appropriate action by seeking medical attention.

If you like genomics, you'll love our question of the week! It's a brand new week, so we have a brand new question. And if you are looking to buy for that hard-to-buy-for person, we have a couple of unique gift ideas!

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Senior genetic counsellor Kirsten Boggs discusses building GCR Connect, the rise of genetic counsellor-led research, and lessons from Mackenzie's Mission - Australia's national reproductive carrier screening study. We explore practical challenges and ethics of large-scale genomic screening, the future of newborn whole-genome programs, consent and data storage issues, and how genetic counsellors can bridge clinical care, research and policy.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2016, Ludovic Orlando, a genetics researcher, embarked on the Pegasus Project, an ambitious endeavor to use genetics to discover the origin of the modern horse. There were plenty of theories as to who domesticated horses first–but Ludovic's team came up with their answer: They emerged on the western Eurasian steppe around 4200 years ago. But that revelation was only the beginning of Ludovic's work, as he dug into the genetic origins of different kinds of horses, like the Arabian horse, as well as charted how the horse's genetic diversity changed over time. His research is collected in his new book Horses: A 4,000-Year Genetic Journey Across the World (Princeton UP, 2025) Ludovic Orlando is a CNRS Silver Medal–winning research director and founding director of the Centre for Anthropobiology and Genomics of Toulouse at the University of Toulouse in France. His work has appeared in leading publications such as Nature, Science, and Cell. He is a recipient of the American Association for the Advancement of Science's Newcomb Cleveland Prize. You can find more reviews, excerpts, interviews, and essays at The Asian Review of Books, including its review of Horses. Follow on Twitter at @BookReviewsAsia. Nicholas Gordon is an editor for a global magazine, and a reviewer for the Asian Review of Books. He can be found on Twitter at@nickrigordon. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In 2016, Ludovic Orlando, a genetics researcher, embarked on the Pegasus Project, an ambitious endeavor to use genetics to discover the origin of the modern horse. There were plenty of theories as to who domesticated horses first–but Ludovic's team came up with their answer: They emerged on the western Eurasian steppe around 4200 years ago. But that revelation was only the beginning of Ludovic's work, as he dug into the genetic origins of different kinds of horses, like the Arabian horse, as well as charted how the horse's genetic diversity changed over time. His research is collected in his new book Horses: A 4,000-Year Genetic Journey Across the World (Princeton UP, 2025) Ludovic Orlando is a CNRS Silver Medal–winning research director and founding director of the Centre for Anthropobiology and Genomics of Toulouse at the University of Toulouse in France. His work has appeared in leading publications such as Nature, Science, and Cell. He is a recipient of the American Association for the Advancement of Science's Newcomb Cleveland Prize. You can find more reviews, excerpts, interviews, and essays at The Asian Review of Books, including its review of Horses. Follow on Twitter at @BookReviewsAsia. Nicholas Gordon is an editor for a global magazine, and a reviewer for the Asian Review of Books. He can be found on Twitter at@nickrigordon.

In 2016, Ludovic Orlando, a genetics researcher, embarked on the Pegasus Project, an ambitious endeavor to use genetics to discover the origin of the modern horse. There were plenty of theories as to who domesticated horses first–but Ludovic's team came up with their answer: They emerged on the western Eurasian steppe around 4200 years ago. But that revelation was only the beginning of Ludovic's work, as he dug into the genetic origins of different kinds of horses, like the Arabian horse, as well as charted how the horse's genetic diversity changed over time. His research is collected in his new book Horses: A 4,000-Year Genetic Journey Across the World (Princeton UP, 2025) Ludovic Orlando is a CNRS Silver Medal–winning research director and founding director of the Centre for Anthropobiology and Genomics of Toulouse at the University of Toulouse in France. His work has appeared in leading publications such as Nature, Science, and Cell. He is a recipient of the American Association for the Advancement of Science's Newcomb Cleveland Prize. You can find more reviews, excerpts, interviews, and essays at The Asian Review of Books, including its review of Horses. Follow on Twitter at @BookReviewsAsia. Nicholas Gordon is an editor for a global magazine, and a reviewer for the Asian Review of Books. He can be found on Twitter at@nickrigordon. Learn more about your ad choices. Visit megaphone.fm/adchoices

In 2016, Ludovic Orlando, a genetics researcher, embarked on the Pegasus Project, an ambitious endeavor to use genetics to discover the origin of the modern horse. There were plenty of theories as to who domesticated horses first–but Ludovic's team came up with their answer: They emerged on the western Eurasian steppe around 4200 years ago. But that revelation was only the beginning of Ludovic's work, as he dug into the genetic origins of different kinds of horses, like the Arabian horse, as well as charted how the horse's genetic diversity changed over time. His research is collected in his new book Horses: A 4,000-Year Genetic Journey Across the World (Princeton UP, 2025) Ludovic Orlando is a CNRS Silver Medal–winning research director and founding director of the Centre for Anthropobiology and Genomics of Toulouse at the University of Toulouse in France. His work has appeared in leading publications such as Nature, Science, and Cell. He is a recipient of the American Association for the Advancement of Science's Newcomb Cleveland Prize. You can find more reviews, excerpts, interviews, and essays at The Asian Review of Books, including its review of Horses. Follow on Twitter at @BookReviewsAsia. Nicholas Gordon is an editor for a global magazine, and a reviewer for the Asian Review of Books. He can be found on Twitter at@nickrigordon. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/asian-review

Jian Lian is an expert on China's political economy, industrial development, and technological development. He graduated from Peking University with a bachelor's and master's degree in economics. Starting out as an industry analyst at a Chinese investment bank, he participated in the "Made in China 2025" initiative as a Chinese venture capitalist, working for a state-owned fund. He is the author of "The Truth About Capital" 资本的真相 (2016), which contains major predictions about technology, economy, and society in China, most of which have since come true.Jian and Steve discuss the origins of the industrial party movement (discussed in an earlier episode with Kyle Chan), which culminated in the "industrial maximalism" view of development adopted by the PRC government. They also discuss the development of supply chains in China, and the role that US sanctions had in accelerating the Chinese semiconductor industry.Kyle Chan episode:https://www.manifold1.com/episodes/kyle-chan-on-the-future-of-us-china-competition-94Chinese industrial maximalism: https://www.high-capacity.com/p/chinese-industrial-maximalism(00:00) - Introduction (00:49) - Jian Gaokao score was 23rd in all of Fujian = Econ at Beida, not Genomics! (05:21) - China's Industrial Policy and Innovation (24:19) - Domestic supply chain strategy; How Huawei became a national champion due to US sanctions (34:13) - Venture Capital in China (36:13) - Hard Tech Investments (37:40) - Regulations of Tech Giants (44:28) - Future of China Technological Development –Steve Hsu is Professor of Theoretical Physics and of Computational Mathematics, Science, and Engineering at Michigan State University. Previously, he was Senior Vice President for Research and Innovation at MSU and Director of the Institute of Theoretical Science at the University of Oregon. Hsu is a startup founder (SuperFocus.ai, SafeWeb, Genomic Prediction, Othram) and advisor to venture capital and other investment firms. He was educated at Caltech and Berkeley, was a Harvard Junior Fellow, and has held faculty positions at Yale, the University of Oregon, and MSU.Please send any questions or suggestions to manifold1podcast@gmail.com or Steve on X @hsu_steve.

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Many nurses lack confidence in applying genomics in practice, highlighting the need for improved genomics nursing education. The International Society for Nurses in Genetics convened a steering committee to develop a competency framework defining the role of Genomics Nurse Educators. This podcast with Dr. Deborah O. Himes presents strategies nurse educators can use to teach genomics application through a nursing program. Read the full article – it is OPEN Access (and share with colleagues).

In this explainer episode, we've asked Amanda Pichini, clinical director at Genomics England and genetic counsellor, to explain what a genetic counsellor is. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What is a genetic counsellor? I'm Florence Cornish, and today I'm joined with Amanda Pichini, a registered genetic counsellor and clinical director for Genomics England, to find out more.   So, before we dive in, lots of our listeners have probably already heard the term genetic counsellor before, or some people might have even come across them in their healthcare journeys. But for those who aren't familiar, could you explain what we mean by a genetic counsellor?  Amanda: Genetic counsellors are healthcare professionals who have training in clinical genomic medicine and counselling skills. So they help people understand complex information, make informed decisions, and adapt to the impact of genomics on their health and their family. They're expert communicators, patient advocates, and navigators of the ethical issues that genomics and genomic testing could bring.  Florence: Could you maybe give me an example of when somebody might see a genetic counsellor?   Amanda: Yes, and what's fascinating about genetic counselling is that it's relevant to a huge range of conditions, scenarios, or points in a person's life.  Someone's journey might start by going to their GP with a question about their health. Let's say they're concerned about having a strong family history of cancer or heart disease, or perhaps a genetic cause is already known because it's been found in a family member and they want to know if they've inherited that genetic change as well.   Or someone might already be being seen in a specialist service, perhaps their child has been diagnosed with a rare condition. A genetic counsellor can help that family explore the wide-ranging impacts of a diagnosis on theirs and their child's life, how it affects their wider family, what it might mean for future children. You might also see a genetic counsellor in private health centres or fertility clinics, or if you're involved in a research study too.   Florence: And so, could you explain a bit more about the types of things a genetic counsellor does? What does your day-to-day look like, for example?   Amanda: Most genetic counsellors in the UK work in the NHS as part of a team alongside doctors, lab scientists, nurses, midwives, or other healthcare professionals. Their daily tasks include things like analysing a family history, assessing the chance of a person inheriting or passing on a condition, facilitating genetic tests, communicating results, supporting family communication, and managing the psychological, the emotional, the social, and the ethical impacts of genetic risk or results.   My day-to-day is different though. I and many other genetic counsellors have taken their skills to other roles that aren't necessarily in a clinic or seeing individual patients. It might involve educating other healthcare professionals or trainees, running their own research, developing policies, working in a lab, or a health tech company, or in the charity sector.   For me, as Clinical Director at Genomics England, I bring my clinical expertise and experience working in the NHS to the services and programmes that we run, and that helps to make sure that we design, implement, and evaluate what we do safely, and with the needs of patients, the public, and healthcare professionals at the heart of what we do.    My day-to-day involves working with colleagues in tech, design, operations, ethics, communications, and engagement, as well as clinical and scientific experts, to develop and run services like the Generation Study, which is sequencing the genomes of 100,000 newborn babies to see if we can better diagnose and treat children with rare conditions.  Florence: So, I would imagine that one of the biggest challenges of being a genetic counsellor is helping patients to kind of make sense of the complicated test results or information, but without overwhelming them. So how do you balance kind of giving people the scientific facts and all the information they need, but while still supporting them emotionally?   Amanda: This is really at the core of what genetic counsellors can do best, I think. Getting a diagnosis of a rare condition, or finding out about a risk that has a genetic component, can come with a huge range of emotions, whether that's worry, fear, or hope and relief.  It can bring a lot of questions, too. What will this mean for my future or my family's future? What do you know about this condition? What sort of symptoms could I have? What treatments or screening might be available to me? So genetic counsellors are able to navigate all of these different questions and reactions by giving an opportunity for patients and families to discuss their opinions, their experiences, and really trying to get at the core of understanding their values, their culture, their expectations, their concerns, so that they can help that individual make an informed decision that's best for them, help them access the right care and support, adjust or find healthy coping strategies, or maybe even change their lifestyle or health behaviours. So it's really finding that balance between the science, the clinical aspects, the information, and the support.  Florence: So obviously working in this space, I get to read about lots of incredible research all the time, and it feels like genetics and genomics seems to be changing and advancing day by day. So, I'd be interested to know what this means for you and for other genetic counsellors, what's coming next?   Amanda: Yeah, so as we continue to see advances in genetics and genomics, there's, I think, a really increasing need for genetic counselling expertise to help shape how these technologies are used and with giving the right consideration for the challenges around what this means for families and for wider society.  Genomics is also still growing the evidence base it needs to provide a consistent and equitable service. We're seeing digital tools being increasingly available to give people information in innovative ways, seeing huge advancements in targeted treatments and gene therapies, that are changing fundamentally the experiences of people living with rare conditions and cancers. And we're using genomics more and more to predict future health risks and how people might respond to certain medications. So, there's a huge amount that we're seeing sort of coming for the future.   What's interesting is the 10-Year Health Plan that the government has set out for the NHS provides, I think, huge opportunities for genomics. For example, we'll see healthcare brought closer to local communities, genomics being used as part of population health, reaching people closer to where they are and hopefully providing greater access.   But I think the key thing in all of this is knowing that genomics is really just a technology. It requires people with the right skill sets to use it safely and to be able to benefit everyone, and genetic counsellors are a huge part of that.   Florence: And finally, in case anyone listening has been inspired by this conversation and wants to build a career like yours, what advice would you have to offer somebody hoping to become a genetic counsellor in the future?   Amanda: To train as a genetic counsellor in the UK, you usually need an undergrad degree in biological sciences, psychology, or being a nurse or midwife. The background can be varied, but usually driven by a common thread, a desire to sort of improve healthcare experiences for patients and make genomic healthcare widely accessible and safely used for everyone.  You can apply for the 3-year NHS scientist training programme, or there's also master's degrees offered through Cardiff University, for example. In general, I'd encourage people to check out the website for the Association of Genetic Nurses and Counsellors, and reach out to genetic counsellors to ask about their career and their journey as much as possible, as well as seeking opportunities to really understand the experiences of people living with rare genetic conditions, because that will help you understand the ways in which genetic counselling can have an impact.  Florence: We'll finish there. Thank you so much, Amanda, for all of those insights and for explaining what it means to be a genetic counsellor. If any listeners want to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk or wherever you get your podcasts.  Thank you for listening. 

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

DAVID MELTZER: PEOPLING OF THE AMERICAS Peopling of the Americas as Inferred from Ancient Genomics 1. Professor David Meltzer, an archaeologist, discusses how genomics provides a breakthrough over earlier methods like mitochondrial DNA by using the entire genome to reveal the complex tapestry of ancestry, showing mixing and cross-breeding among populations. Ancestral Native Americans arose from the admixture of Ancient North Siberians and an East Asian population around 26,000 to 24,000 years ago. During the last glacial maximum (23,000–19,000 years ago), lower sea levels exposed the land bridge connecting Siberia and Alaska, and these distinctive ancestral groups became isolated due to harsh glacial cold, positioning themselves to move further south.

Patterns of Isolation and Continuity in the Americas 4. Professor Meltzer notes that rapid dispersal and substantial population increase characterized the first peoples in the Americas, leading to early isolation and the emergence of subgroups through both geographic constraints like the Andes Mountains and social isolation due to increasing territoriality. Some areas show strong genomic continuity over millennia while others show discontinuity, with populations being displaced or replaced, and later influxes occurred around 6,000 years ago as maritime groups began crossing the Bering Sea, causing further admixture. Genomics is also used to study indigenous health history, including the incidence of diseases like tuberculosis, to help present-day descendants and confirm the devastating impact of infectious diseases introduced by Europeans.

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"[When] a lot of men think about prostate exams, they immediately think of the glove going on the hand of the physician, and they immediately clench. But really try to talk with them and discuss with them what some of the benefits are of understanding early detection. Even just having those conversations with their providers so that they understand what the risk and benefits are of having screening. And then educate patients on what a prostate-specific antigen (PSA) and digital rectal exam (DRE) actually are—how it happens, what it shows, and what the necessary benefits of those are," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer screening, early detection, and disparities. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to prostate screening, early detection, and disparities. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ Episode 149: Health Disparities and Barriers in Metastatic Castration-Sensitive Prostate Cancer ONS Voice articles: Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment Leveling State-Level Tax Policies May Increase Equality in Cancer Screening and Mortality Rates Most Cancer Screening Guidelines Don't Disclose Potential Harms ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Barriers and Solutions to Cancer Screening in Gender Minority Populations Oncology Nursing Forum articles: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics Other ONS resources: Genomics and Precision Oncology Learning Library ONS Biomarker Database (refine by prostate cancer) American Cancer Society prostate cancer early detection, diagnosis, and staging page National Institutes of Health prostate cancer screening page U.S. Preventive Services Task Force prostate cancer screening recommendation statement To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The recommendations are men [aged] 45 who are at high risk, including African American men and men who have a first-degree relative who has been diagnosed with prostate cancer younger than 65 should go through screening. And men aged 40 at an even higher risk, these are the men that have that one first-degree relative who has had prostate cancer before 65. Screening includes the PSA blood test and a digital exam. Those are the screening recommendations, although they are a little bit controversial." TS 3:42 "You still see PSAs and DREs as the first line because they're easier for primary care providers to perform. ... Those are typically covered by insurance, so they still play that role in screening. But with the advent of MRIs and biomarkers, these have really helped refine that screening process and determine treatment options for our patients. Again, those patients who may be at a bit of a higher risk could go for an MRI or have biomarkers completed. Or if they're on that verge with their Gleason score, instead of doing a biopsy, they may send the patient for an MRI or do biomarkers for that patient. ... These updated technologies put [patients] a little bit more at ease that someone's watching what's going on, and they don't have to have anything invasive done to see where they're at with their staging." TS 4:35 "Disparities in screening access exist based on race, socioeconomic status, gender identity, education, and geography. It's really hard in rural areas to get primary care providers or urologists who can actually see these patients, [and] sometimes in urban areas. So socioeconomic status can affect that, but also where a person lives. African American men with lower incomes and people in rural areas face the greatest barriers to receiving screening. It's also important to encourage anyone with a prostate to be screened and offer gender-neutral settings for patients to feel comfortable." TS 7:50 "I think a lot of men feel like if they have no symptoms, they don't have prostate cancer ... so a lot of patients may put off screening because they feel fine, [they] haven't had any urinary symptoms, it doesn't run in their family. ...With prostate cancer, there usually are not symptoms that a patient's having—they may have some urinary issues or some pain—but it's not very frequent that they have that. So, just making sure our patients understand that even though they're not feeling something, it doesn't mean there's not something else going on there." TS 12:53 "Prostate cancer found at an early age can be very curable, so it's really important for men to have those conversations with their providers about the risk and benefits of screening. And anyone that we can help along the way to be able to have those conversations, I think is a great thing for oncology nurses to do." TS 15:44

In this episode of Ageless Future, Regan Archibald sits down with Dr. Aaron Hartman, a leading integrative and functional medicine physician from Richmond, Virginia, to explore how personal struggle reshaped his medical philosophy. Dr. Hartman shares the remarkable story of his adopted daughter, Anna, who was born with severe neurological challenges after prenatal drug exposure and was given little hope by conventional medicine. Refusing invasive interventions, Dr. Hartman and his wife instead pioneered a personalized, root-cause approach—combining nutrition, genomic testing, hyperbaric therapy, peptides, and stem cells—to help Anna achieve milestones doctors said were impossible. Their journey reveals both the shortcomings of standard medical systems and the transformative power of curiosity, persistence, and faith. The conversation expands to the healing of mothers, trauma recovery, and how functional medicine empowers both patients and practitioners to think, innovate, and restore true health. LIKE/FOLLOW/SUBSCRIBE DR. HARTMAN:Website: https://uncurablebook.com/YouTube: https://www.youtube.com/c/AaronHartmanMDInstagram: https://www.instagram.com/rvaintegrative/Facebook: https://www.facebook.com/RVAintegrativeLIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube: https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureInstagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Host Matt Burgess talks with Dr Jodie Ingles, a leading cardiac genetic counsellor and researcher, about inherited heart conditions, supporting families after sudden cardiac events, and translating genomic discoveries into clinical care. The episode covers variant classification, health equity, the evolving role of genetic counsellors, and the importance of mentorship and practical changes needed to bring genomic testing into everyday practice.

It's The Ranch It Up Radio Show! Join Jeff Tigger Erhardt, Rebecca Wanner AKA BEC and their crew as they hear the latest reactions to potential imports of Argentine Beef.  Plus, part 2 of genomically testing the cow herd and when it comes to nutrition, don't forget about the bulls.  Plus, market reports, upcoming sales and lots more on this all-new episode of The Ranch It Up Radio Show.  Be sure to subscribe on your favorite podcasting app or on the Ranch It Up Radio Show YouTube Channel. Season 5, EPISODE 260 Cattle & Producer Groups React To Potential Imports of Argentine Beef   Last Sunday President Donald Trump said the United States could purchase Argentinian beef in an attempt to bring down prices for American consumers.  This sparked immediate reaction from our cattle associations and organizations. Reference: https://apnews.com/article/beef-argentina-us-consumers-prices-f7fadbe1b3fef4646f9c3623f901209a National Cattlemen's Beef Association (NCBA) Reaction To Argentine Beef NCBA's family farmers and ranchers have numerous concerns with importing more Argentinian beef to lower prices for consumers. This plan only creates chaos at a critical time of the year for American cattle producers, while doing nothing to lower grocery store prices," said NCBA CEO Colin Woodall. "Additionally, Argentina has a deeply unbalanced trade relationship with the U.S. In the past five years Argentina has sold more than $801 million of beef into the U.S. market. By comparison, the U.S. has sold just over $7 million worth of American beef to Argentina. Argentina also has a history of foot-and-mouth disease, which if brought to the United States, could decimate our domestic livestock production. REFERENCE: https://www.nationalbeefwire.com/ncba-argentinian-beef-import-plan-harms-u-s-cattle-producers United States Cattlemen's Association (USCA) Reaction To Argentine Beef The current price of beef on grocery store shelves reflects the true, inflation-adjusted cost of raising cattle in America today.  Already this year, the U.S. has imported more than 1.26 million metric tons of beef, primarily from Australia, Canada, Brazil, Mexico, and New Zealand. Increasing imports under current rules ultimately benefits foreign suppliers and multinational packers, while putting U.S. ranchers on the losing end and depriving American consumers of honest transparency at the meat counter. REFERENCE: https://www.nationalbeefwire.com/usca-comments-on-president-trump-s-remarks-regarding-beef-prices-and-proposed-imports-from-argentina R-Calf USA Reaction To Argentine Beef Global packers are importing beef from about 20 different countries, including Argentina, and because we do not have a mandatory country-of-origin labeling law for beef, the global packers do not need to reduce the price of imported product compared to domestic product. This negates any theoretical benefit of using more imports to drive down domestic beef prices. We urge the president to manage imports, restore mandatory country-of-origin labeling for beef, and put an end to the monopolistic control that packers and retailers have over our beef supply chain. Doing so will incentivize America's ranchers to rebuild and expand the U.S. herd to meet our national security needs and ensure that consumer beef prices are determined by competitive market forces. REFERENCE: https://www.nationalbeefwire.com/statement-on-plan-to-increase-argentine-beef-imports Fall Bull Nutrition From Westway Feed Products Nutritional balance is a cornerstone of herd health and productivity. According to Dr. Kelly Sanders of Westway Feed Products, deficiencies often go unnoticed until performance suffers. Signs Of Nutritional Deficiencies In Cattle Poor Body Condition: Thin cows, visible ribs, or weak muscling. Reduced Fertility: Open cows, delayed cycling, or poor conception rates. Coat and Hoof Issues: Rough hair coats, brittle hooves, or slow shedding. Growth Challenges in Calves: Reduced weight gains or uneven growth patterns. How To Correct Deficiencies Forage Testing: Identify nutrient gaps in hay and pasture. Targeted Supplementation: Provide liquid or block supplements to balance protein, energy, and minerals. Management Adjustments: Ensure adequate feed availability during high-demand stages such as lactation and breeding. Dr. Sanders emphasizes that proactive nutrition not only boosts herd performance but also maximizes returns on investment in genetics. Ideal Beef Genetics:  The Power Of Genomics In The Cow Herd   The Science of Selection With GEPDs from the Ideal Beef Evaluation, selecting replacement females becomes a science, not an art. Using 15 different traits, and custom indexes that combine and simplify them, phenotype and pedigree are no longer the only tools at your disposal to guide the future of your herd. Prove Your Pedigree Genotyping your herd with IBG allows parentage verification so you know where your herd comes from. All Herd and AI sires available from Jorgensen Land and Cattle are genotyped and available for sire match, and all of your genotyped females will match with their progeny. The Power of Genomic Analytics Visualize Your Results Enrolling your cattle in the IBG service gives you access to AgBoost, a revolutionary technology that turns confusing genomic results into easy to understand visualizations. This allows you to cut through the clutter and focus on your herd's future. Matings Made Easy Females enrolled in IBG are eligible for breeding suggestions powered by industry leading analytics. You pick your desired breeding outcomes, and your females will be analyzed next to Jorgensen Land and Cattles 5000+ Herd and AI sire battery, ensuring the bulls you turn out are the best for your herd's future. Enroll Cow Herd In Genomic Testing With Jorgensen Land & Cattle Gather Tissue Samples:  TSU's and Collectors are available at no charge upon request Send Samples & Data:  We handle ordering test, shipping samples & delivery of results Review Your Results: Evaluation results are loaded into your AgBoost Profile, so you are sure to have the most up to date & accurate GEPD's at your disposal Select Your Females: Use your herd's genomics to pick the best females to keep Select Your Bulls: We work with you to determine the breeding outcomes best for your herd and pick bulls that best meet those needs Featured Experts in the Cattle Industry Dr. Kelly Sanders – Westway Feed Products https://westwayfeed.com/ Follow on Facebook: @WestwayFeed Larry Gran – Jorgensen Land & Cattle https://jorgensenfarms.com/ Follow on Facebook: @JorLandCat Mark Vanzee – Livestock, Equine, & Auction Time Expert https://www.auctiontime.com/ https://www.livestockmarket.com/ https://www.equinemarket.com/ Follow on Facebook: @LivestockMkt | @EquineMkt | @AuctionTime Kirk Donsbach – Financial Analyst at StoneX https://www.stonex.com/ Follow on Facebook: @StoneXGroupInc Shaye Wanner – Host of Casual Cattle Conversation https://www.casualcattleconversations.com/ Follow on Facebook: @cattleconvos Contact Us with Questions or Concerns Have questions or feedback? Feel free to reach out via: Call/Text: 707-RANCH20 or 707-726-2420 Email: RanchItUpShow@gmail.com Follow us: Facebook/Instagram: @RanchItUpShow YouTube: Subscribe to Ranch It Up Channel: https://www.youtube.com/c/RanchItUp Catch all episodes of the Ranch It Up Podcast available on all major podcasting platforms. Discover the Heart of Rural America with Tigger & BEC Ranching, farming, and the Western lifestyle are at the heart of everything we do. Tigger & BEC bring you exclusive insights from the world of working ranches, cattle farming, and sustainable beef production. Learn more about Jeff 'Tigger' Erhardt & Rebecca Wanner (BEC) and their mission to promote the Western way of life at Tigger and BEC. https://tiggerandbec.com/ Industry References, Partners and Resources For additional information on industry trends, products, and services, check out these trusted resources: Allied Genetic Resources: https://alliedgeneticresources.com/ American Gelbvieh Association: https://gelbvieh.org/ Axiota Animal Health: https://axiota.com/multimin-campaign-landing-page/ Imogene Ingredients: https://www.imogeneingredients.com/ Jorgensen Land & Cattle: https://jorgensenfarms.com/#/?ranchchannel=view Medora Boot: https://medoraboot.com/ RFD-TV: https://www.rfdtv.com/ Rural Radio Network: https://www.ruralradio147.com/ Superior Livestock Auctions: https://superiorlivestock.com/ Transova Genetics: https://transova.com/ Westway Feed Products: https://westwayfeed.com/ Wrangler: https://www.wrangler.com/ Wulf Cattle: https://www.wulfcattle.com/

In this episode, host Lindsey Elizabeth Cortes, a sports dietitian and entrepreneur, delves into the world of female athlete nutrition with guest Nick Padula, a private practice sports dietitian and professor at the University of Southern California. They discuss the importance of personalized nutrition, the impact of dietary choices on performance, and the power of comprehensive testing, including continuous glucose monitors (CGMs), genomics, and microbiome analysis.   Nick shares his experiences working with various athletes, from boxers to endurance runners, and underscores how detailed nutrition data can significantly enhance training and recovery. Lindsey and Nick also explore practical approaches to fueling for both everyday athletes and elite sports performers, emphasizing the difference between generalized guidelines and individualized nutritional insights.   Episode Highlights: 01:24 Meet Nick Padula: Sports Dietician Extraordinaire 02:50 The Intersection of Clinical and Sports Nutrition 04:14 The Science and Ethics of Weight Cutting 09:52 Customizing Nutrition Through Testing 17:06 Understanding Genomic and Microbiome Testing 26:26 Addressing RED-S and Support Options 29:13 Understanding Gluten Intolerance 32:28 The Role of Continuous Glucose Monitors (CGMs) 35:37 Practical Applications of CGMs 42:05 The Importance of Recovery Nutrition 45:30 Exploring Nutrition Packages and Testing 47:07 The Impact of Environmental Toxins 53:31 Fun Questions and Final Thoughts Nick Padula has been a practicing Dietitian since 2015 as a clinical dietitian, a foodservice director. In addition to You Trition, LBC Nutrition, a dietetic consultant company, is a lecturer and coordinator with the University of Southern California Master’s in Nutrition program and Sports Dietitian for Cypress Junior College Athletics. ⁠   Nick studied nutrition and dietetics at Long Beach State University and received a Bachelor's degree in 2012 and Master's degree in Nutrition and Dietetics with a concentration in Sports Nutrition from Texas Tech University. ⁠In his practice he has worked with triathletes, professional boxers, endurance runners, professional soccer players, high school athletes, and the USC football and basketball teams. Nick is an avid runner, weightlifter, and golfer.   Connect with Nick: www.youtritionscience.com IG:@Youtrition_science Email: nick@youtritionscience.com   Resources and Links: For more information about the show, head to work with Lindsey on improving your nutrition, head to: http://www.lindseycortes.com/ Join REDS Recovery Membership: http://www.lindseycortes.com/reds WaveBye Supplements – Menstrual cycle support code LindseyCortes for 15% off: http://wavebye.co Previnex Supplements – Joint Health Plus, Muscle Health Plus, plant-based protein, probiotics, and more; code riseup for 15% off: previnex.com Female Athlete Nutrition Podcast Archive & Search Tool – Search by sport, condition, or topic: lindseycortes.com/podcast Female Athlete Nutrition Community – YouTube, Instagram @‌femaleathletenutrition, and private Facebook group

Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today's biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution. They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education. Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he's helping grow a Chicago-centered biotech ecosystem. Biography: Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma. Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology. Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH). Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if the next major leap in aquaculture doesn't come from the ocean but from the genome? In this week's episode, we trace the story of genomic sequencing: from Darwin's first evolutionary trees to the breakthroughs that now let scientists map entire fish genomes in a single day. You'll learn how falling sequencing costs are opening the door to disease tracing, genetic selection, and smarter breeding programs that could redefine sustainability across aquaculture. For more aquaculture insights head to our Fish n' Bits blog.

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Addiction doesn't announce itself- it emerges silently, often after a routine medical procedure. Our next guest, James Piacentino, is changing this reality as CEO and Co-Founder of Thrive Genetics. With over 20 years in healthcare technology and two successful startup exits under his belt, James brings both personal experience and professional expertise to this mission. After losing his father to opioid addiction following a routine surgery, James dedicated his career to ensuring others wouldn't face the same tragedy. By combining cutting-edge genomics with behavioral psychology, Thrive Genetics helps physicians understand a patient's addiction risk before prescribing pain medication. Join us to discover how James and his team are pioneering personalized addiction risk management, transforming how healthcare systems approach prevention, and working to spare millions of families from generational trauma. Let's go!Episode Highlights:Curiosity as the foundation for innovation: James emphasizes that deep curiosity about solving meaningful problems is the key driver that gets him out of bed every morning and the most important quality he looks for in team members.Personal tragedy sparking a mission: After losing his father to opioid addiction following a 1982 car accident and back surgery, James dedicated his career to preventing others from experiencing the same generational trauma.Staggering gap in care: Up to 25% of patients undergoing high-pain procedures become addicted to prescribed opioids, yet no proactive addiction risk assessment exists before prescribing pain medication.Science-backed solution: Thrive Genetics combines 10 years of research and over $50M in NIH grants to create addiction risk scores based on both genetic predisposition (50%) and behavioral factors (50%).Thinking beyond the individual: James' North Star is reaching billions of people by preventing not just individual addiction cases, but stopping generational family trauma before it starts.About our Guest: Thrive Genetics is led by Co-Founder and CEO, James J. Piacentino, MBA, a healthcare technology entrepreneur with over 20 years in tech and life sciences. A graduate of Northwestern University's Kellogg School of Management, James has built and sold two prior startups, published in the Harvard Business Review, and held senior leadership roles at SAP. He is mentored by Harry Kraemer, former CEO of Baxter International and Kellogg Professor of Management.Links Supporting This Episode: Thrive Genetics Website: CLICK HEREJame Piacentino LinkedIn page: CLICK HEREThrive Genetics LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter:

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Deanna Saylor talks with Dr. Senjuti Saha about colonialism in global health and the importance of pathogen genomics.  Read the related article in The Lancet.  Disclosures can be found at Neurology.org.